Corbus Logo.jpg
Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO GU
18 déc. 2023 08h00 HE | Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today...
Corbus Logo.jpg
Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
07 nov. 2023 08h00 HE | Corbus Pharmaceuticals Holdings, Inc.
Data from dose escalation study for CRB-701, a Nectin-4 ADC to treat solid tumors, on track for release in early 2024 along with start of U.S./EU StudyIND Submission for CRB-601, an αvβ8 Monoclonal...
Corbus Logo.jpg
Corbus Pharmaceuticals Presents Results of Two Pre-Clinical Studies on its Anti-αVβ8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting
02 nov. 2023 08h00 HE | Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company, today announced that results from...
Corbus Logo.jpg
Corbus Pharmaceuticals Announces Publication of Data for its Novel Cannabinoid Type-1 Receptor Inverse Agonist in a Pre-Clinical Model of Obesity Along with Presentations at Obesity Week 2023
17 oct. 2023 08h00 HE | Corbus Pharmaceuticals Holdings, Inc.
CRB-913 is a novel highly peripherally restricted CB1 inverse agonist with potent monotherapy efficacy in DIO mouse modelWeight loss and related outcomes markedly enhanced in combination with...
Corbus Logo.jpg
Corbus Pharmaceuticals Presents the First Pre-Clinical Characterization of its Next Generation Nectin-4 ADC CRB-701
16 oct. 2023 08h00 HE | Corbus Pharmaceuticals Holdings, Inc.
CRB-701 demonstrates a differentiated nonclinical profile relative to enfortumab vedotinEarly dose escalation clinical data supports differentiating features established pre-clinicallyThe company on...
Corbus Logo.jpg
Corbus Pharmaceuticals to Host Virtual ‘Meet the Expert’ Series (Session 2) on CRB-701 on October 10, 2023
03 oct. 2023 08h00 HE | Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that it will host a...
logo.png
Corbus Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Updates
12 août 2021 08h05 HE | Corbus Pharmaceuticals Holdings, Inc.
Company focused on gaining regulatory clarity for late-stage lenabasum program and advancing programs targeting the endocannabinoid system and integrins into the clinicAugmenting the pipeline through...
logo.png
Corbus Pharmaceuticals Announces Topline Results from DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
24 juin 2021 08h05 HE | Corbus Pharmaceuticals Holdings, Inc.
Study did not meet primary endpoint of Total Improvement Score (TIS) at Week 28Additional findings included nominally significant improvements in TIS (p = 0.0302) and CDASI (p = 0.0166) depending on...
logo.png
Corbus Pharmaceuticals Licenses Two Integrin Targeting mAbs Further Expanding Pipeline into Cancer and Fibrotic Diseases
01 juin 2021 07h05 HE | Corbus Pharmaceuticals Holdings, Inc.
Corbus diversifies pipeline with two new mAbs that target integrins that inhibit activation of TGFβ High potency anti-αvβ8 mAb licensed from University of California San Francisco and...
logo.png
Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2021 Virtual Congress
25 mai 2021 08h05 HE | Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, May 25, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative...